<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vestnovsu</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник Новгородского государственного университета</journal-title><trans-title-group xml:lang="en"><trans-title>Vestnik of Novgorod State University</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-8052</issn><publisher><publisher-name>Новгородский государственный университет имени Ярослава Мудрого</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.34680/2076-8052.2025.4(142).587-602</article-id><article-id custom-type="elpub" pub-id-type="custom">vestnovsu-424</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Патологическая физиология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Pathophysiology</subject></subj-group></article-categories><title-group><article-title>Влияние мелатонина в составе ректальных суппозиториев на показатели при TNBS-индуцированном колите</article-title><trans-title-group xml:lang="en"><trans-title>Effect of melatonin in rectal suppositories on oxidative stress parameters in TNBS-induced colitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6487-9083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осиков</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Osikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осиков Михаил Владимирович – доктор медицинских наук, профессор, профессор РАН, заведующий кафедрой; начальник отдела научной работы</p><p>Челябинск</p></bio><bio xml:lang="en"><p>Chelyabinsk</p></bio><email xlink:type="simple">prof.osikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2537-0158</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грекова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grekova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грекова Ирина Викторовна – старший преподаватель</p><p>Челябинск</p></bio><bio xml:lang="en"><p>Chelyabinsk</p></bio><email xlink:type="simple">irkraft@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Южно-Уральский государственный медицинский университет; Челябинская областная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University; Chelyabinsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Южно-Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2026</year></pub-date><volume>0</volume><issue>4(142)</issue><fpage>587</fpage><lpage>602</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осиков М.В., Грекова И.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Осиков М.В., Грекова И.В.</copyright-holder><copyright-holder xml:lang="en">Osikov M.V., Grekova I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnovsu.elpub.ru/jour/article/view/424">https://vestnovsu.elpub.ru/jour/article/view/424</self-uri><abstract><p>Окислительный стресс – ключевое звено патогенеза воспалительных заболеваний кишечника. Мелатонин – эндогенный регулятор гомеостаза с плейотропными, в том числе антиоксидантными, свойствами, его ректальные формы в РФ не зарегистрированы. Цель исследования – изучить влияние мелатонина в составе оригинальных ректальных суппозиториев на показатели окислительного стресса при экспериментальном колите, индуцированном 2,4,6-тринитробензолсульфоновой кислотой (TNBS-ИК). 64 крысы линии Wistar были распределены на 4 группы: интактная, TNBS-ИК, TNBS-ИК + ректальные суппозитории с мелатонином, TNBS-ИК + ректальные суппозитории без активного компонента. Модель TNBS-ИК воспроизводили еженедельным ректальным введением TNBS в возрастающих дозах (15–60 мг/кг) в течение 6 недель. Оценивали индекс активности болезни, концентрацию фекального кальпротектина, содержание продуктов перекисного окисления липидов и общий антиоксидантный статус в слизистой оболочке очага повреждения толстой кишки. Модель TNBS-ИК у крыс воспроизводила клинические и лабораторные проявления воспалительных заболеваний кишечника. Установлено, что применение ректальных суппозиториев с мелатонином при TNBS-ИК приводило к снижению индекса активности болезни и концентрации фекального кальпротектина, уменьшению содержания продуктов перекисного окисления липидов и повышению общего антиоксидантного статуса по сравнению с группами TNBS-ИК и TNBS-ИК с ректальными суппозиториями без активного компонента. Полученные данные демонстрируют эффективность мелатонина в составе ректальных суппозиториев при TNBS-ИК и являются предпосылкой для проведения дальнейших исследований возможного их применения в составе комплексной терапии при воспалительных заболеваниях кишечника.</p></abstract><trans-abstract xml:lang="en"><p>Oxidative stress is a key component in the pathogenesis of inflammatory bowel diseas. Melatonin is an endogenous regulator of homeostasis with pleiotropic properties, including antioxidant effects; rectal formulations of melatonin are not registered in the Russian Federation. The aim of research was to study the effect of melatonin incorporated into original rectal suppositories on oxidative stress parameters in experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS colitis). Sixty-four Wistar rats were divided into four groups: intact; TNBS colitis; TNBS colitis + rectal suppositories with melatonin; TNBS colitis + rectal suppositories without active component (placebo). The TNBS colitis model was reproduced by weekly rectal administration of TNBS in increasing doses (15–60 mg/kg) for 6 weeks. The disease activity index, fecal calprotectin concentration, levels of lipid peroxidation products, and total antioxidant status in the colonic mucosa at the site of injury were assessed. The TNBS colitis model in rats reproduces clinical and laboratory manifestations of inflammatory bowel disease. It was found that the use of rectal suppositories with melatonin in TNBS colitis led to a decrease in disease activity index and fecal calprotectin concentration, a decrease in the content of lipid peroxidation products, and an increase in total antioxidant status compared with the TNBS colitis and TNBS colitis groups with rectal suppositories without an active component. The obtained data demonstrate the efficacy of melatonin in rectal suppositories in TNBS colitis and provide a rationale for further studies, as well as for the potential use of melatonin–containing rectal suppositories as part of combination therapy for inflammatory bowel disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>TNBS-индуцированный колит</kwd><kwd>окислительный стресс</kwd><kwd>перекисное окисление липидов</kwd><kwd>антиоксидантный статус</kwd><kwd>мелатонин</kwd><kwd>ректальные суппозитории</kwd></kwd-group><kwd-group xml:lang="en"><kwd>TNBS-induced colitis</kwd><kwd>oxidative stress</kwd><kwd>lipid peroxidation</kwd><kwd>antioxidant status</kwd><kwd>melatonin</kwd><kwd>rectal suppositories</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Siew C., Shi H. Y., Hamidi H., Fox E., Tang W., Benchimol E. I., Panaccione R., Ghosh S., Wu J. C. Y., Chan A. K. L., Sung J. J. S., Kaplan G. G. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies // Lancet. 2018. 390 (10114). 2769–2778. DOI: 10.1016/S0140-6736(17)32448-0</mixed-citation><mixed-citation xml:lang="en">Siew C., Shi H. Y., Hamidi H., Fox E., Tang W. , Benchimol  E. I., Panaccione R., Ghosh S., Wu J. C. Y., Chan A. K. L., Sung J. J. S., Kaplan G. G. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies // Lancet. 2018. 390 (10114). 2769–2778. DOI: 10.1016/S0140-6736(17)32448-0</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">the Coward S., Benchimol E. I., Kuenzig M. E., Windsor J. W., Bernstein C. N., Bitton A., Jones J. L., Lee K., Murthy S. K., Targownik L. E., Peña-Sánchez J.-N., Rohatinsky N., Ghandeharian S., Im J. H. B., Davis T., Weinstein J., Goddard Q., Bennett J., Caplan L., Bergevin M., Yang X. Y., Mason K., Sanderson R., Brass C., Kaplan G. G. The 2023 Impact of inflammatory bowel disease in Canada: epidemiology of IBD // Journal of Canadian association of gastroenterology. 2023. 6 (2). S9–S15. DOI: 10.1093/jcag/gwad004</mixed-citation><mixed-citation xml:lang="en">the Coward S., Benchimol E. I., Kuenzig M. E., Windsor  J. W., Bernstein C. N., Bitton A., Jones J. L., Lee K., Murthy S. K., Targownik L. E., Peña-Sánchez J.-N., Rohatinsky N., Ghandeharian S., Im J. H. B., Davis T., Weinstein J., Goddard Q., Bennett J., Caplan L., Bergevin M., Yang X. Y., Mason K., Sanderson R., Brass C., Kaplan G. G. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD // Journal of Canadian association of gastroenterology. 2023. 6 (2). S9–S15. DOI: 10.1093/jcag/gwad004</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Белоусова Е. А., Шелыгин Ю. А., Ачкасов С. И., Хатьков И. Е., Бакулин И. Г., Скалинская М. И., Князев О. В., Каграманова А. В., Шкурко Т. В., Нанаева Б. А., Никитина Н. В., Захарова М. Н., Тарасова Л. В., Алексеева О. П., Злобин М. В., Павленко В. В., Мищенко Е. В., Долгушина А. И., Лахин А. В., Ткачев А. В., Абдулганиева Д. И., Васильева О. В., Губонина И. В. Клинико демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа национального Регистра // Колопроктология. 2023. 22 (1). 65–82. DOI: 10.33878/2073-7556-2023-22-1-65-82</mixed-citation><mixed-citation xml:lang="en">Belousova E. A., Shelygin Yu. A., Achkasov S. I., Khatkov I. E., Bakulin I. G., Skalinskaya M. I., Knyazev O. V., Kagramanova A. V., Shkurko T. V., Nanaeva B. A., Nikitina N. V., Zakharova M. N., Tarasova L. V., Alekseeva O. P., Zlobin M. V., Pavlenko V. V., Mishchenko E. V., Dolgushina A. I., Lakhin A. V., Tkachev A. V., Abdulganieva D. I., Vasilyeva O. V., Gubonina I. V. Clinical and demographic characteristics and therapeutic approaches in patients with inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russian Federation: first results of the analysis of the national Registry // Koloproktologia. 2023. 22 (1). 65–82. DOI: 10.33878/2073-7556-2023-22-1-6582 (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Muro P., Zhang L., Li S., Zhao Z., Jin T., Mao F., Mao Z. The emerging role of oxidative stress in inflammatory bowel disease // Frontiers in endocrinology. 2024. 15 (1390351). DOI: 10.3389/fendo.2024.1390351</mixed-citation><mixed-citation xml:lang="en">Muro P., Zhang L., Li S., Zhao Z., Jin T., Mao F., Mao Z. The emerging role of oxidative stress in inflammatory bowel disease // Frontiers in endocrinology. 2024. 15 (1390351). DOI: 10.3389/fendo.2024.1390351</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sahoo D. K., Heilmann R. M., Paital B., Patel A., Yadav V. K., Wong D., Jergens A. E. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease // Frontiers in endocrinology. 2023. 14 (1217165). DOI: 10.3389/fendo.2023.1217165</mixed-citation><mixed-citation xml:lang="en">Sahoo D. K., Heilmann R. M., Paital B., Patel A., Yadav V. K., Wong D., Jergens A. E. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease // Frontiers in endocrinology. 2023. 14 (1217165). DOI: 10.3389/fendo.2023.1217165</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sebastian S. A., Kaiwan O., Co E. L., Mehendale M., Mohan B. P. Current pharmacologic options and emerging therapeutic approaches for the management of ulcerative colitis: a narrative review // Spartan medical research journal. 2024. 9 (3). 123397. DOI: 10.51894/001c.123397</mixed-citation><mixed-citation xml:lang="en">Sebastian S. A., Kaiwan O., Co E. L., Mehendale M., Mohan B. P. Current pharmacologic options and emerging therapeutic approaches for the management of ulcerative colitis: a narrative review // Spartan medical research journal. 2024. 9 (3). 123397. DOI: 10.51894/001c.123397</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Morris G. P., Beck P. L., Herridge M. S., Depew W. T., Szewczuk M. R., Wallace J. L. Hapten-induced model of chronic inflammation and ulceration in the rat colon // Gastroenterology. 1989. 96 (3). 795–803. DOI: 10.1016/0016-5085(89)90904-9</mixed-citation><mixed-citation xml:lang="en">Morris G. P., Beck P. L., Herridge M. S., Depew W. T., Szewczuk M. R., Wallace J. L. Hapten-induced model of chronic inflammation and ulceration in the rat colon // Gastroenterology. 1989. 96 (3). 795–803. DOI: 10.1016/0016-5085(89)90904-9</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bondy S.C., Campbell A. Melatonin and regulation of immune function: impact on numerous diseases // Current aging science. 2020. 13 (2). 92–101. DOI: 10.2174/1874609813666200711153223</mixed-citation><mixed-citation xml:lang="en">Bondy S.C., Campbell A. Melatonin and regulation of immune function: impact on numerous diseases // Current aging science. 2020. 13 (2). 92–101. DOI: 10.2174/1874609813666200711153223</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muñoz-Jurado A., Escribano B. M., Caballero-Villarraso J., Galván A., Agüera E., Santamaría A., Túnez I. Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action // Inflammopharmacology. 2022. 30. 1569–1596. DOI: 10.1007/s10787-022-01011-0</mixed-citation><mixed-citation xml:lang="en">Muñoz-Jurado A., Escribano B. M., Caballero-Villarraso J., Galván A., Agüera E., Santamaría A., Túnez I. Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action // Inflammopharmacology. 2022. 30. 1569–1596. DOI: 10.1007/s10787-022-01011-0</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Директива Европейского парламента и Совета Европейского Союза 2010/63/EC от 22 сентября 2010 г. о защите животных, использующихся для научных целей. URL: https://base.garant.ru/70350564 (Дата обращения: 01.02.2025).</mixed-citation><mixed-citation xml:lang="en">Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. URL: https://base.garant.ru/70350564 (Accessed: 01.02.2025). (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stidham R. W., Xu J., Johnson L. A., Kim K., Moons D. S., McKenna B. J., Rubin J. M., Higgins P. D. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn’s disease // Gastroenterology. 2011. 141 (3). 819–826.e1. DOI: 10.1053/j.gastro.2011.07.027</mixed-citation><mixed-citation xml:lang="en">Stidham R. W., Xu J., Johnson L. A., Kim K., Moons D. S., McKenna B. J., Rubin J. M., Higgins P. D. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn’s disease // Gastroenterology. 2011. 141 (3). 819–826.e1. DOI: 10.1053/j.gastro.2011.07.027</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Осиков М. В., Ушакова В. А., Грекова И. В., Бойко М. С., Гречишкин М. В. Патент № 2819721 C1 Российская Федерация, МПК A61K 9/02, A61K 31/4045, A61P 29/00. Средство с мелатонином для терапии воспалительных заболеваний кишечника в форме ректальных суппозиториев: № 2023114954: заявл. 07.06.2023: опубл. 23.05.2024; заявитель Федеральное государственное бюджетное образовательное учреждение высшего образования «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации.</mixed-citation><mixed-citation xml:lang="en">Osikov M. V., Ushakova V. A., Grekova I. V., Boyko M. S., Grechishkin M. V. Patent №. 2819721 C1, Russian Federation, IPC A61K 9/02, A61K 31/4045, A61P 29/00. Melatonin-containing agent for the treatment of inflammatory bowel diseases in the form of rectal suppositories. Appl. №. 2023114954, filed 07.06.2023; publ. 23.05.2024. Applicant: South Ural State Medical University, Ministry of Health of the Russian Federation (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Best W. R., Becktel J. M., Singleton J. W., Kern F. Development of a Crohn’s disease activity index // Gastroenterology. 1976. 70 (3). 439–444.</mixed-citation><mixed-citation xml:lang="en">Best W. R., Becktel J. M., Singleton J. W., Kern F. Development of a Crohn’s disease activity index // Gastroenterology. 1976. 70 (3). 439–444.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper H. S., Murthy S. N., Shah R. S., Sedergran D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis // Laboratory investigation. 1993. 69 (2). 238–249.</mixed-citation><mixed-citation xml:lang="en">Cooper H. S., Murthy S. N., Shah R. S., Sedergran D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis // Laboratory investigation. 1993. 69 (2). 238–249.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Волчегорский И. А., Налимов А. Г., Яровинский Б. Г., Лифшиц Р. И. Сопоставление различных подходов к определению продуктов перекисного окисления липидов в гептан-изопропанольных экстрактах крови // Вопросы медицинской химии. 1989. 35 (1). 127–131.</mixed-citation><mixed-citation xml:lang="en">Volchegorsky I. A., Nalimov A. G., Yarovinsky B. G., Lifshits R. I. Comparison of different approaches to the determination of lipid peroxidation products in heptane-isopropanol blood extracts // Problems of medical chemistry. 1989.  35 (1). 127–131. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Xu M., Qian W., Ling F., Chen Y., Li S., Cheng Y., Zhuet L. Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn’s disease // Frontiers in physiology. 2023. 14. 1186665. DOI: 10.3389/fphys.2023.1186665</mixed-citation><mixed-citation xml:lang="en">Li J., Xu M., Qian W., Ling F., Chen Y., Li S., Cheng Y., Zhuet L. Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn’s disease // Frontiers in physiology. 2023. 14. 1186665. DOI: 10.3389/fphys.2023.1186665</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Li L., Peng P. L., Ding N., Jia W. H., Huang C. H., Tang Y. Oxidative stress, inflammation, gut dysbiosis: what can polyphenols do in inflammatory bowel disease? // Antioxidants. 2023. 12 (4). 967. DOI: 10.3390/antiox12040967</mixed-citation><mixed-citation xml:lang="en">Li L., Peng P. L., Ding N., Jia W. H., Huang C. H., Tang Y. Oxidative stress, inflammation, gut dysbiosis: what can polyphenols do in inflammatory bowel disease? // Antioxidants. 2023. 12 (4). 967. DOI: 10.3390/antiox12040967</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Araruna M. E. C., Júnior E. B. A., de Lima Serafim K. A., Pessoa M. M. B., Pessôa M. L. S., Alves V. P., Sobral M. V., da Silva M. S., Alves A. F., de Paiva Sousa M. C., Araújo A. A., Batista L. B. (-)-Fenchone ameliorates TNBS-induced colitis in rats via antioxidant, immunomodulatory, and cytoprotective mechanisms // Pharmaceuticals (Basel). 2024. 18 (1). 18. DOI: 10.3390/ph18010018</mixed-citation><mixed-citation xml:lang="en">Araruna M. E. C., Júnior E. B. A., de Lima Serafim K. A., Pessoa M. M. B., Pessôa M. L. S., Alves V. P., Sobral M. V., da Silva M. S., Alves A. F., de Paiva Sousa M. C., Araújo A. A., Batista L. B. (-)-Fenchone ameliorates TNBS-induced colitis in rats via antioxidant, immunomodulatory, and cytoprotective mechanisms // Pharmaceuticals (Basel). 2024. 18 (1). 18. DOI: 10.3390/ph18010018</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Costa Monteiro K. K. A., Shiroma M. E., Damous L. L., de Jesus Simões M., Dos Santos Simões R., Cipolla-Neto J., Baracat E. C., Soares-Jr X. M. Antioxidant actions of melatonin: a systematic review of animal studies // Antioxidants. 2024. 13 (4). 439. DOI: 10.3390/antiox13040439</mixed-citation><mixed-citation xml:lang="en">Costa Monteiro K. K. A., Shiroma M. E., Damous L. L., de Jesus Simões M., Dos Santos Simões R., Cipolla-Neto J., Baracat E. C., Soares-Jr X. M. Antioxidant actions of melatonin: a systematic review of animal studies // Antioxidants. 2024. 13 (4). 439. DOI: 10.3390/antiox13040439</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Brazão V., Colato R.P., Santello F. H., Duarte A., Goulart A., Sampaio P. A., Silva C. B. P., Tirapelli C. R., Costa R. M., Tostes R. C., do Prado Jr J. C. Melatonin regulates antioxidant defense and inflammatory response by activating Nrf2-dependent mechanisms and inhibiting NFkappaB expression in middle-aged T. cruzi infected rats // Experimental gerontology. 2022. 167. 111895. DOI: 10.1016/j.exger.2022.111895</mixed-citation><mixed-citation xml:lang="en">Brazão V., Colato R.P., Santello F. H., Duarte A., Goulart A., Sampaio P. A., Silva C. B. P., Tirapelli C. R., Costa R. M., Tostes R. C., do Prado Jr J. C. Melatonin regulates antioxidant defense and inflammatory response by activating Nrf2-dependent mechanisms and inhibiting NFkappaB expression in middle-aged T. cruzi infected rats // Experimental gerontology. 2022. 167. 111895. DOI: 10.1016/j.exger.2022.111895</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tiong Y. L., Ng K. Y., Koh R. Y., Ponnudurai G., Chye S. M. Melatonin prevents oxidative stress-induced mitochondrial dysfunction and apoptosis in high glucose-treated Schwann cells via upregulation of Bcl2, NF-κB, mTOR, Wnt signalling pathways // Antioxidants. 2019. 8 (7). 198. DOI: 10.3390/antiox8070198</mixed-citation><mixed-citation xml:lang="en">Tiong Y. L., Ng K. Y., Koh R. Y., Ponnudurai G., Chye S. M. Melatonin prevents oxidative stress-induced mitochondrial dysfunction and apoptosis in high glucose-treated Schwann cells via upregulation of Bcl2, NF-κB, mTOR, Wnt signalling pathways // Antioxidants. 2019. 8 (7). 198. DOI: 10.3390/antiox8070198</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
